Revenue segments as reported by the company.

Pharmacy revenues

Premiums

Fees and other revenues

Net investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Pharmacy and other service costs

Medical costs and other benefit expenses

Selling, general and administrative expenses

Amortization of acquired intangible assets

Special items

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cigna

Express Scripts is a company that provides integrated pharmacy benefit management services including network-pharmacy claims processing; home delivery pharmacy services; specialty pharmacy benefit management, through its subsidiary Accredo; benefit-design consultation; drug-utilization review; formulary management; and medical and drug data analysis services to manage drug plans for health plans, self-insured employers and government agencies (both as administrator of employee benefits and public assistance programs). Express Scripts also offers pharmacy benefit management services for workers' compensation insurance programs. The program is accredited by URAC, the nation's largest accrediting body for pharmacy benefit management companies. The company processes pharmaceutical claims for members through a network of retail pharmacies. Its own automated pharmacies dispense long-term, chronic medications-like those for diabetes or heart disease-directly to members by home delivery.

Express Scripts

The Cigna Group is a global health company, which engages in the provision of global health services. It operates through the following segments: Evernorth Health Services, Cigna Healthcare, Other Operations, and Corporate. The Evernorth Health Services segment partners with health plans, employers, governmental organizations, and health care providers to solve challenges in the areas of pharmacy benefits, home delivery pharmacy, specialty pharmacy, specialty distribution, and care delivery and management solutions. The Cigna Healthcare segment includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical and coordinated solutions to clients and customers. The Other Operations segment consists of the remainder of business operations, which includes certain ongoing businesses and exited businesses. The Corporate segment refers to net interest expense, certain litigation matters, expense associated with frozen pension plans, charitable contributions, operating severance, certain overhead and enterprise-wide project costs, and eliminations for products and services sold between segments. The company was founded in 1792 and is headquartered in Bloomfield, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cigna posts strong Q4 earnings, eyes growth in specialized services

Cigna delivered strong financial results in Q4 2022, with robust revenue growth and operational performance across key business segments.
While facing challenges such as margin pressures and potential disenrollment, Cigna is well-positioned to capitalize on growth opportunities in 2023.
Strategic partnerships, customer-focused strategies, and financial discipline underscore Cigna's commitment to sustainable growth and shareholder value creation.
Investments in innovation, care coordination, and market expansion signal a proactive approach to navigating industry dynamics and driving future success.

Cigna reports robust Q1 earnings, eyes growth amid challenges

Cigna's Q1 2023 showcased strong financials, growth in key segments, and increased outlook.
Challenges include economic softening impact and margin expectations for the year.
Opportunities lie in customer relationships, innovation, and market-specific strategies.
Overall, Cigna remains confident in delivering on its financial and growth targets.

Cigna reports robust Q2 results, eyes growth through innovation

Cigna's Q2 2023 performance was strong, with revenue growth, customer expansion, and technological advancements driving positive outcomes.
While facing challenges like disenrollment and risk adjustment payables, Cigna is leveraging strengths in technology and cross-selling for growth.
Opportunities lie in partnerships like VillageMD, continued innovation, and strategic bidding strategies for future growth.
Overall, Cigna remains confident in delivering on adjusted EPS outlook for 2023 and 2024, with a focus on innovation and growth.

Cigna surpasses Q3 expectations, eyes $28 EPS in 2024

Cigna's Q3 performance exceeded expectations, driven by strong revenue and EPS growth across key business segments.
Strategic focus on innovation, affordability, and client partnerships positions Cigna well for future growth and value creation.
Challenges in margin expectations and enrollment declines require proactive management and strategic decision-making.
Opportunities lie in continued growth projections, strategic investments, and enhancing healthcare affordability and accessibility.

Cigna reports robust Q4 performance, eyes growth amid strategic changes

Cigna Group's Q4 2023 Earnings Call highlighted strong financial performance, leadership changes, and strategic decisions. Analyst inquiries focused on growth drivers, market outlook, and internal healthcare spend management. The outlook for 2024 includes expectations of solid adjusted EPS, revenue growth, and operating cash flow.

Cigna surpasses Q1 expectations, eyes growth through AI and biosimilars

Cigna's Q1 performance exceeded expectations, driven by strong revenue and EPS figures.
Despite challenges like noncash losses and disruptions, Cigna's strategic strengths in AI, biosimilars, and value-based care position it well for growth.
Opportunities in AI-driven healthcare solutions, biosimilar expansions, and strategic M&A offer avenues for future growth.
Cigna's focus on precision care solutions and client outcomes showcases its commitment to innovation and efficiency.

Cigna (CI) posts robust Q2 results, eyes biosimilar growth

Cigna (CI) reports strong Q2 financial results driven by Evernorth Health Services and Express Scripts' innovative programs.
Focus on affordability, access, and behavioral health services propels growth in U.S. employer business.
Challenges include navigating healthcare cost pressures and ensuring fair pricing negotiations.
Opportunities lie in biosimilar growth, sustainable revenue outlook, and strategic Medicare Advantage business sale.

Cigna reports robust Q3 earnings, eyes growth opportunities in 2025

Cigna's Q3 earnings call highlighted strong financial performance, strategic focus on shareholder value, and challenges in specialty drugs and cost trends. The company is optimistic about opportunities in 2025 and remains committed to delivering shareholder value through strategic initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ares Management

Broadcom

Carlisle Companies

Dick's Sporting Goods

Comfort Systems USA

Hartford Financial Services Group

Intuit

Martin Marietta Materials

Microsoft

NRG Energy

Owens Corning

QUALCOMM

Wingstop

This article focuses on selecting high-growth dividend stocks that have rapidly grown their dividends in the recent past, rather than simply sport a high current yield. We use our proprietary models to rate quantitatively and qualitatively and select the top ten names from an initial list of nearly 400 dividend stocks. The article provides criteria for selecting high-growth dividend stocks. It offers a step-by-step guide on structuring a portfolio based on this strategy.

Our Top 10 Dividend Growth Stocks - April 2024

Cigna (CI) closed at $348.78 in the latest trading session, marking a +0.78% move from the prior day.

Why the Market Dipped But Cigna (CI) Gained Today

Grant application now open for nonprofits that aim to improve youth mental health  New multiyear philanthropic and community engagement initiative will also prioritize the mental health of veterans through housing stability and reducing barriers to health equity Initiative encourages employee volunteerism, and launches with volunteer events to assemble mental well-being packs for local Boys & Girls Clubs BLOOMFIELD, Conn. , April 18, 2024 /PRNewswire/ -- As part of its ongoing commitment to community health and vitality, global health company The Cigna Group (NYSE: CI) today announced a multiyear philanthropic and community engagement initiative focused on partnering with nonprofit organizations with expertise in three essential areas: improving youth mental health, bolstering veteran mental health through housing stability and services, and addressing barriers to health equity.

The Cigna Group Foundation Announces New Grant Program To Address Youth Mental Health Crisis

BLOOMFIELD, Conn. , April 11, 2024 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) will release its first quarter 2024 financial results on Thursday, May 2, 2024, and will host a conference call the same day.

The Cigna Group's First Quarter 2024 Earnings Release Details

Company Recognized for Excellence in Health Equity         BLOOMFIELD, Conn. , April 9, 2024 /PRNewswire/ -- Global health company The Cigna Group (NYSE: CI) has been recognized for excellence in employee health and well-being by the Business Group on Health, and for its commitment to health equity.

The Cigna Group Named Among Best Employers for Health and Well-Being

The Cigna Group is one of the few companies that have outperformed the AI-fantasy-driven S&P 500 Index by a wide margin. After a 50% return in less than a year and a new all-time high, it's fair to ask whether it's wise to sell Cigna stock now. In this update, I share my view on Cigna's performance in 2023 and explain why I decided to hold on to my Cigna shares - despite the historically expensive valuation.

Cigna: Time To Sell The Stock After A 50% Return? No, Here's Why

Humana

Investors with an interest in Medical - HMOs stocks have likely encountered both Cigna (CI) and Humana (HUM). But which of these two stocks is more attractive to value investors?

CI vs. HUM: Which Stock Is the Better Value Option?

Intuitive Surgical

Eli Lilly

PureCycle Technologies

Simplify Health Care ETF

Sarepta Therapeutics

The Simplify Health Care exchange-traded fund has grown to $136 million in assets in two and a half years. It is never easy for an actively managed fund to outperform its benchmark or a broad stock-market index, but Michael Taylor, the fund's lead manager, has done that so far.

Outperforming ETF manager names a potential ‘50-bagger' in the stock market

SYDNEY--(BUSINESS WIRE)--Global health insurance brokerage Pacific Prime Dubai has been awarded the Top Producing Broker Asia Award by Cigna at the Global Broker Advisory Council (GBAC) Awards, held in Sydney, Australia, from March 11th to 14th. In recognition of their outstanding work and commitment in the insurance brokerage industry, the Top Producing Broker Asia Award showcases Pacific Prime Dubai's dedication to exceeding client expectations and providing comprehensive insurance solutions.

Pacific Prime Wins Cigna Global's Top Producing Broker Asia Award 2024

Affiliated Managers

Barrett Business Services

JAKKS Pacific

KB Home

The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like KBH, AMG, CI, BBSI and JAKK hold promise.

5 Low Price-to-Sales Stocks Poised to Race up the Charts

Allstate

General Motors

Kroger

Mohawk Industries

Phillips 66

Target

Travelers

Valero Energy

Value stocks in the S&P 500 are perking up. And investors are moving fast to buy some up while they're still cheap.

11 Value Stocks Are Dirt Cheap — But Won't Stay That Way For Long

HCA Healthcare

The recent uptick in U.S. manufacturing signals a promising trend for the economy. Investor confidence in the economy's stability is reflected in the decreasing odds for a June rate cut, indicating optimism about future monetary policy.

The 3 Best Healthcare Stocks to Buy in April 2024

UnitedHealth Group

Health insurance stocks are falling on Tuesday after President Joe Biden's Administration announced it won't increase Medicare Advantage rates for 2025. This comes as a surprise to health insurance companies as the government typically increases its rates compared to its initial proposals.

Why Are Health Insurance Stocks HUM, UNH, CI Down Today?

Cigna's Evernorth Services segment, fueled by the acquisition of Express Scripts in 2018, is well positioned to benefit from innovation in drugs and specialty pharmacy. The company's management prioritizes shareholder returns and has infused growth into its outlook, inspiring investors. Cigna's outlook and investor day presentation suggests it can reach a target of $400+ and has strong growth potential.

Cigna Continues To Reap Gains From A Shrewd Acquisition Made In 2018

Cigna (CI) reachead $363.34 at the closing of the latest trading day, reflecting a +1.57% change compared to its last close.

Cigna (CI) Surpasses Market Returns: Some Facts Worth Knowing

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Brokers Suggest Investing in Cigna Group (CI): Read This Before Placing a Bet

eBay

Eaton

Parker-Hannifin

Ralph Lauren

We have narrowed our search to five non-tech S&P 500 stocks that have provided double-digit returns year to date. These are: CI, RL, PH, ETN, EBAY.

S&P 500 Achieves a New Milestone: Top 5 Non-Tech Picks

In the most recent trading session, Cigna (CI) closed at $352.63, indicating a +0.16% shift from the previous trading day.

Cigna (CI) Increases Yet Falls Behind Market: What Investors Need to Know

Investors looking for stocks in the Medical - HMOs sector might want to consider either Cigna (CI) or Humana (HUM). But which of these two stocks offers value investors a better bang for their buck right now?

CI or HUM: Which Is the Better Value Stock Right Now?

Fidelis Insurance Holdings Ltd

PagSeguro Digital

The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like PAGS, AMG, CI, BBSI and FIHL hold promise.

5 Low Price-to-Sales Stocks to Fetch Solid Portfolio Gains

Cigna (CI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Cigna Group (CI) Soars to 52-Week High, Time to Cash Out?

The Cigna Group (CI) Presents at Barclays 26th Annual Global Healthcare Conference Transcript

Cigna's (CI) strong Evernorth and Cigna Healthcare segments, value enhancing initiatives and a positive 2024 outlook poise it well for growth.

Here's Why You Should Add Cigna (CI) Stock to Your Portfolio

Cigna (CI) currently estimates long-term average annual adjusted EPS growth within 10-14%. It also came up with new solutions to better manage the rising GLP-1 costs and expand behavioral care.

Cigna (CI) Unveils Updated Long-Term Growth Targets & Solutions

Cigna Group (CI) said it has taken steps to control the cost and increase coverage of diabetes and weight-loss medicines, which have experienced a boom in demand by those looking to shed pounds.

News for Cigna Stock (CI)